Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Denmark

Marie Skłodowska-Curie Action · Running

TRANSCEND Transcending limitations of translational research on Multiple Sclerosis and Autism Spectrum Disorder - Spectral, brain-related disorder, patient outcomes, cognition, effect, symptoms

Coordinator
Aarhus Universitet, Denmark
Runs
1 September 2025 to 31 August 2029
Status
Running
EU funding
€4.0m
Total cost
—
Partners
22 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226660

What the project is doing

In the project's own words, from its summary on CORDIS.

TRANSCEND brings together expertise in biomedical, computational, behavioural, clinical, epidemiological and philosophicalresearch to advance translational research in medicine. TRANSCEND aims to add to the chronological and epistemic order of research from bench to bedside to practice with a more networked-based understanding of translation. This is particularly important in translational research on complex and chronic neurological conditions where the few low-hanging fruits of reductionist approaches seem to have been picked.

TRANSCEND involves nine interlinked laboratories from clinical, biomedical, metamethodological, and philosophical sub-projects, which focus on autism spectrum disorder and multiple sclerosis. These conditions are characterised by an interconnected set of physical, cognitive and psychological symptoms, and unknown underlying disease mechanisms. While healthcare has been moving away from a purely single-cause view of medicine towards interconnected concepts of positive health, such a more complicated and nuanced notion of health and dis/ability is unintegrated within biomedical research.

Most research designs are not well-suited to consider patient-relevant outcomes, the biological and social complexity of these conditions, and their implications in real-world healthcare settings, because their epistemology is oriented towards purification and reduction concerning research questions, disease models, and experiments. TRANSCEND proposes an integrative approach to translational research that embraces instead of reduces the complexity and diversity of the biological, clinical and social manifestations of the diagnoses.

It will provide an innovative, interdisciplinary training along four research objectives to overcome key limitations of translational research on complex, chronic conditions: (1) making animal models more translational; (2) focusing on patient outcomes and scoping “disease” categories; (3) rethinking theragnostic strategies.

Topics

Who is involved

OrganisationCityCountryRole
Aarhus UniversitetAarhus CDenmarkCoordinator
European Animal Research AssociationBruxelles / BrusselBelgiumAssociatedpartner
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Idorsia Pharmaceuticals LtdAllschwilSwitzerlandAssociatedpartner
Bundesministerium Fuer GesundheitBonnGermanyAssociatedpartner
Universitaet BielefeldBielefeldGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Saber BioParisFranceAssociatedpartner
Universite Bordeaux MontaignePessac CedexFranceParticipant
Ospedale San Raffaele SRLMilanoItalyAssociatedpartner
Universita Vita-Salute San RaffaeleMilanoItalyParticipant
Ink BVAmsterdamNetherlandsAssociatedpartner
Orikami B.V.NijmegenNetherlandsAssociatedpartner
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Radboud UniversiteitNijmegenNetherlandsParticipant
Stichting MS ResearchVoorschotenNetherlandsAssociatedpartner
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit UtrechtUtrechtNetherlandsAssociatedpartner
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En PatientenzorgAmsterdamNetherlandsAssociatedpartner
Universitetet I OsloOsloNorwayParticipant
Universidade Do PortoPortoPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS